MTA1抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MTA1 mouse mAb (green) and negative control (red).    

  
  

The MTA1 (Metastasis-associated protein 1) antibody is a critical tool for studying the role of the MTA1 protein in cellular processes and disease pathogenesis. MTA1. a member of the MTA protein family, was first identified as a metastasis-regulating factor in cancer. It functions as a transcriptional coregulator within the nucleosome remodeling and histone deacetylation (NuRD) complex, modulating gene expression by altering chromatin structure. MTA1 is implicated in diverse pathways, including DNA repair, cell proliferation, epithelial-mesenchymal transition (EMT), and angiogenesis, with overexpression observed in numerous cancers (e.g., breast, prostate, colorectal) linked to metastasis, therapy resistance, and poor prognosis.

MTA1 antibodies are designed to detect endogenous MTA1 isoforms (∼80 kDa) and are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). These antibodies help researchers investigate MTA1's subcellular localization (primarily nuclear), expression levels in pathological vs. normal tissues, and interactions with binding partners (e.g., ERα, HIF-1α). Validating antibody specificity is crucial due to potential cross-reactivity with homologous family members (MTA2. MTA3). Both monoclonal and polyclonal variants are available, with clones like D4E7 (CST) and EP1003Y commonly cited. Recent studies also explore MTA1's non-oncogenic roles in inflammation, neurodegeneration, and metabolic disorders, broadening the antibody's research applications.